TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07032662: A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor: Immunovant Sciences GmbH · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 162 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$465,600

Rescue Site Savings

+$310,400

Unlock Full NCT07032662 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07032662 Rescue Dossier →